secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMARIN CORP PLCUK (AMRN)
CIK:        0000897448
Form:       8-K
Filed at:   2024-06-04T23:59:59+00:00
Accession:  0000950170-24-068298
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amarin CEO resigns; large PBM to drop Vascepa coverage July 1, affecting 25% of US volume
--------------------------------------------------------------------------------

- CEO Pat Holt resigned; Aaron Berg appointed as President & CEO effective June 4, 2024.
- Holt will provide consulting services through July 3, 2024 in exchange for his base salary.
- A large national PBM will exclude Vascepa from commercial national formularies effective July 1, 2024.
- Affected formularies represent ~25% of aggregate US Vascepa prescription volume; Medicare Part D unaffected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/897448/000095017024068298/0000950170-24-068298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/897448/000095017024068298/amrn-20240603.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-068298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer